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Abstract: OBJECTIVES Decellularized aortic homografts (DAH) may provide an additional aortic valve
replacement option for young patients due to their potential to overcome the high early failure rate of con-
ventional allogenic and xenogenic aortic valve prostheses. METHODS A prospective, European Union-
funded, single-arm, multicentre, safety study was conducted in 8 centres evaluating non-cryopreserved
DAH for aortic valve replacement. RESULTS One hundred and forty-four patients (99 male) were
prospectively enrolled between October 2015 and October 2018, mean age 33.6 ± 20.8 years; 45% had
undergone previous cardiac operations. Mean implanted DAH diameter 22.6 ± 2.4 mm and mean dura-
tions for the operation, cardiopulmonary bypass and cross-clamp were 341 ± 140, 174 ± 80 and 126 ±
43 min, respectively. There were 2 early deaths (1 LCA thrombus on day 3 and 1 ventricular arrhythmia
5 h postop) and 1 late death due to endocarditis 4 months postoperatively, resulting in a total mortal-
ity of 2.08%. One pacemaker implantation was necessary and 1 DAH was successfully repaired after 6
weeks for early regurgitation following subcoronary implantation. All other DAH were implanted as a
free-standing root. After a mean follow-up of 1.54 ± 0.81 years, the primary efficacy end points peak
gradient (mean 11.8 ± 7.5 mmHg) and regurgitation (mean 0.42 ± 0.49, grade 0-3) were excellent. At
2.5 years, freedom from explantation/endocarditis/bleeding/stroke was 98.4 ± 1.1%/99.4 ± 0.6%/99.1 ±
0.9%/99.2 ± 0.8%, respectively, with results almost identical to those in an age-matched Ross operation
cohort of 212 patients (mean age 34 years) despite DAH patients having undergone >2× more previous
procedures. CONCLUSIONS The initial results of the prospective multicentre ARISE trial show DAH
to be safe for aortic valve replacement with excellent haemodynamics in the short follow-up period.
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OBJECTIVES: Decellularized aortic homografts (DAH) may provide an additional aortic valve replacement option for young patients due
to their potential to overcome the high early failure rate of conventional allogenic and xenogenic aortic valve prostheses.
METHODS: A prospective, European Union-funded, single-arm, multicentre, safety study was conducted in 8 centres evaluating non-
cryopreserved DAH for aortic valve replacement.
RESULTS: One hundred and forty-four patients (99 male) were prospectively enrolled between October 2015 and October 2018, mean
age 33.6 ± 20.8 years; 45% had undergone previous cardiac operations. Mean implanted DAH diameter 22.6 ± 2.4mm and mean durations
for the operation, cardiopulmonary bypass and cross-clamp were 341 ± 140, 174 ± 80 and 126 ± 43min, respectively. There were 2 early
deaths (1 LCA thrombus on day 3 and 1 ventricular arrhythmia 5 h postop) and 1 late death due to endocarditis 4 months postoperatively,
resulting in a total mortality of 2.08%. One pacemaker implantation was necessary and 1 DAH was successfully repaired after 6 weeks for
early regurgitation following subcoronary implantation. All other DAH were implanted as a free-standing root. After a mean follow-up of
1.54 ± 0.81 years, the primary efficacy end points peak gradient (mean 11.8 ± 7.5mmHg) and regurgitation (mean 0.42 ± 0.49, grade 0–3)
were excellent. At 2.5 years, freedom from explantation/endocarditis/bleeding/stroke was 98.4 ± 1.1%/99.4 ± 0.6%/99.1 ± 0.9%/99.2 ± 0.8%,
respectively, with results almost identical to those in an age-matched Ross operation cohort of 212 patients (mean age 34 years) despite
DAH patients having undergone >2more previous procedures.
CONCLUSIONS: The initial results of the prospective multicentre ARISE trial show DAH to be safe for aortic valve replacement with excel-
lent haemodynamics in the short follow-up period.
Keywords: Aortic valve disease • Tissue engineering • Decellularization • Allografts
ABBREVIATIONS
AVR Aortic valve replacement
CPB Cardiopulmonary bypass
DAH Decellularized aortic homograft
INTRODUCTION
Aortic valve replacement (AVR) in young adult patients still presents
a major challenge with a difficult choice between multiple subopti-
mal surgical options for patients once valve repair is not feasible.
Conventional xenogenic biological heart valve prostheses have
shown limited durability, especially in very young patients. In some
cases, rapid deterioration of valve function has even resulted in
sudden cardiac death [1]. However, the option of industrially man-
ufactured biological valves is nevertheless preferable for some
patients, despite the associated higher reoperation rates, as it does
not require lifelong anticoagulation medication [2, 3].
Mechanical valves provide excellent long-term durability and
are the method of choice for AVR in patients under 50 years of
age in many centres worldwide [3, 4]. However, active patients
and women wishing to start a family more frequently struggle
with the inherent restrictions associated with in the strict, lifelong
anticoagulation regime required to avoid mechanical valve
thrombosis. In addition, there is a 1–1.5% risk of a severe bleed-
ing or thrombotic event per patient-year [4]. The next generation
of anticoagulants will hopefully help to reduce this risk in young
patients, which appears considerable, given today’s life expect-
ancy. Until then, this risk can be minimized through patient edu-
cation and anticoagulation self-management strategies [5].
The Ross autograft operation is considered the gold-standard
for AVR in young patients [6]. However, despite the excellent
long-term results reported for the procedure, it has not been
adapted by the vast majority of cardiac surgeons due to its tech-
nical complexity and a reluctance to create a potential 2-valve
problem for the patient in the future. In addition, a significant
number of patients undergoing AVR are not good candidates for
a Ross procedure, a fact sometimes neglected by advocates of
the approach. Patients with bicuspid aortic valves, rheumatic or
connective tissue disease and patients with associated dilatation
of the ascending aorta are not ideal Ross candidates. The same
applies for patients with comorbid mitral disease or multiple pre-
vious AVR due to congenital heart defects.
Cryopreserved human aortic valves are currently rarely used
for planned AVR, as durability in young patients is limited due to
pronounced calcification, leading to increased morbidity during
redo operations. In extensive aortic root endocarditis, allograft
AVR remains the procedure of choice due to the unique ability
to restore normal anatomy [7, 8].
Decellularized allografts have been in clinical use for more
than a decade and may provide an additional AVR option for
young patients, as they can potentially overcome the high early
failure rate of conventional allogenic and xenogeneic AVR pros-
theses due to reduced immunogenicity [9, 10]. There have been
conflicting reports on the results of various processing methods
used for decellularization, which have led to calls for prospective
long-term studies on decellularized allografts for AVR [11–13].
The aim of this study therefore is to (i) present early data from
the first prospective, European-wide trial on decellularized aortic
homograft (DAH) for AVR and (ii) to compare current DAH
results from the ARISE Registry with contemporary data on the
Ross procedure and other AVR options for young adults.
MATERIALS AND METHODS
Study setting
The ARISE study received funding from the European Union’s
HORIZON 2020 Programme under grant agreement no. 643597.
The funding covered homograft procurement, homograft proc-
essing and data collection. Corlife oHG provided the decellulari-
zation service for the homografts and sponsored the study
according to good clinical practice requirements.














































































The study was registered under ClinicalTrials.gov, NCT02
527629, and received the European Network of Centers for
Pharmacoepidemiology and Pharmacovigilance (ENCePPV
R
) seal as
a Post Authorization Safety Study, EU PAS 10201. The study was
also registered with the German Federal Institute for Vaccines and
Biomedicines (www.pei.de) under Ref. Number NIS322.
Approval was given by all local ethics committees prior to the
start of the study, and informed consent was obtained appropriately
from all participants or parents (MHH no. 2840-2015). Indication
for AVR according to the 2017 European Society of Cardiology/
European Association for Cardio-Thoracic Surgery guidelines for
valvular heart disease was the key inclusion criterion without age
limits; patients with active endocarditis were excluded.
Patients were not included consecutively and patient selection
was based on the decision of the respective centre, availability of
an appropriate homograft and patient consent. Surgical proce-
dures were performed according to locally established standard
procedures under cardiopulmonary bypass (CPB). Postoperative
anticoagulation with Warfarin was recommended for 2 months,
followed by ASA at 100mg per day to be continued as a perman-
ent medication regime.
The calculated sample size was 120 patients based on the aver-
age of 5.4% adverse clinical events per patient-year reported for
mechanical valves and biological valves during follow-up, including
sustained structural valve deterioration, non-structural valve dys-
function, thromboembolism and bleeding, and endocarditis [8].
The primary end points were periprocedural complications (all-
cause mortality, major stroke, life-threatening or disabling bleeding,
acute kidney injury requiring renal replacement therapy, myocar-
dial infarction, major vascular complications) and heart valve dys-
function (aortic valve area <_ 1.2 cm2 and mean aortic valve
gradient >_ 20mmHg or peak velocity >_ 3m/s, or moderate or se-
vere prosthetic valve aortic regurgitation) and repeat procedure for
valve-related dysfunction (surgical or interventional therapy).
Homograft procurement and processing
Homografts were procured in line with the current European
Directive 2004/23, as amended, via 4 different tissue banks
(European Homograft Bank, Brussels, Dr R. Jashari; German
Society for Tissue Transplantation—DGFG, Hannover, M. Börgel;
EuroTissue Bank, Rotterdam, A. van den Bogaerdt; Banc de Sang i
Teixits, Barcelona, Dr E. Trias) and shipped to Hannover for proc-
essing at corlife oHG (www.corlife.eu).
DAH was authorized by the German competent authority as
the medicinal product ‘Cell-free aortic heart valve, Arise AV’, #
PEI.G.11766.01.1. The processing of each homograft comprises
30 different steps using a detergent-based, non-cryopreserva-
tion approach as described previously [14]. Microbiological as-
sessment was performed as part of the incoming inspection,
both during and after processing with a final 14-day quarantine.
Each homograft was assessed histologically following processing,
and the residual dsDNA content was measured after processing
and prior to final release. Reference samples of all homografts
were stored in accordance with German law for at least 1 year.
Statistical analysis
Summaries of numeric data are given as means and standard de-
viation. The proportion of explanted and dysfunctional grafts
over time was calculated and a peak echocardiographic gradient
of >_ 50mmHg and regurgitation >_ moderate was defined as
dysfunctional.
Time-related events, such as freedom from explantation and
degeneration, were evaluated according to Kaplan–Meier.
We calculated perioperative and annual adverse events such as
death, reoperation or reintervention, valve degeneration, throm-
botic and bleeding events and endocarditis for all DAH
implanted to date from the ARISE Registry, which has a 100%
follow-up of all patients having received a DAH to date, and
compared them with the results of recent large-scale meta-analy-
ses for bioprostheses, mechanical valves and the Ross procedure
in young adults, provided by the group of Johanna Takkenberg.
We also included the actually observed freedom from any ad-
verse event curve for DAH ±95% confidence intervals to this
comparison to allow for direct comparison [4, 15, 16].
The long-term extrapolation was performed by simply adding
the observed early and annual rates for adverse incidents. Annual
event rates were calculated based on the respective event-free
patient fraction to date.
We did not test for statistical significance due to the significant
differences in data sets, i.e. prospectively collected data from a
controlled multicentre trial and meta-analyses summarizing al-
most entirely retrospective and single-centre studies and the lim-
ited follow-up of the DAH cohort.




One hundred and forty-four patients (99 male) were prospect-
ively enrolled in the ARISE Trial between October 2015 and
October 2018 with a mean age of 33.6 ± 20.8 years. Twenty-
eight percent were paediatric patients and 45% of the patients
had undergone previous cardiac operations. Nineteen percent
underwent 2 or more previous surgical procedures. The mean
implanted DAH diameter was 22.6 ± 2.4mm. The mean oper-
ation duration was 341 ± 1.40min, the mean CPB time was
174 ± 80min and the mean cross-clamp time 126 ± 43min. No
postoperative bypass grafting or renal replacement therapy was
required.
Figure 1 shows the patient numbers per site within the ARISE
study. Table 1 gives an overview of the characteristics of the
ARISE study cohort and the ARISE Registry cohort of all DAH
implanted to date. This registry includes the ARISE study patients
and all patients having received DAH prior to and outside the
clinical study, e.g. in centres, which did not participate in the
ARISE study.
There were 2 early deaths in the cohort: 1 patient suffered car-
diac arrest due to an LCA thrombus on postoperative day 3 while
on the normal ward and subsequently died, despite extracorpor-
eal assist due to multi-organ failure. The most likely explanation
was an embolus from the left atrium associated with a simultan-
eous mitral valve procedure during DAH implantation, as emer-
gency coronary angiography showed no stenosis at ostial level or
any kinking of the main stem.
The other patient died due to sustained ventricular arrhythmia
5 h postoperatively despite extracorporeal assist for a suspected
coronary reimplantation problem following explantation of a







































































































showed patent coronary arteries and normal suture lines as well
as severe left ventricular hypertrophy and an old myocardial
infarction, which occurred during implantation of the cryopre-
served homograft 18 years ago. In addition, 1 further patient died
4months postoperatively during introduction of anaesthesia for
reoperation due to endocarditis-associated complications, result-
ing in a total mortality of 2.08%.
One pacemaker implantation was necessary for atrioventricular
block and 1 DAH was successfully repaired for early regurgitation
after 6weeks. No signs of endocarditis were observed during redo,
and technical problems in the initial operation were identified.
This was also the only DAH implanted in subcoronary position;
all other DAHs were implanted as free-standing root replace-
ments without significant reinforcement procedures.
Table 1: Patient characteristics for the ARISE study and the ARISE Registry cohort including all DAH implanted to date
ARISE study cohort (N = 144) All DAH (N = 223)
Implantation period 2015–2018 2008–2019
Age at implantation (years), mean (SD) 33.6 (20.8) 28.7 (19.8)
Follow-up (years), mean (SD) 1.54 (0.81) 2.60 (2.13)
Total follow-up (years), n 222 581
Male gender, n (%) 99 (69) 151 (68)





Type of previous procedures, n
1 aortic valve replacement 19 30
2 aortic valve replacement 5 8
Catheter-based intervention 23 48
Aortic valve repair 6 23




Implantation time (min), mean (SD)
Total operation 341 (140) 348 (131)
Cardiopulmonary bypass 174 (80) 190 (88)
Cross-clamp 126 (43) 132 (46)
Latest echocardiography
Aortic annulus (mm), mean (SD) 23.7 (2.5) 21.9 (4.0)
Aortic annulus, z-score, mean (SD) 0.53 (1.6) 0.20 (1.51)
Effective orifice area (cm2), mean (SD) 3.1 (0.9) 2.9 (0.8)
Peak gradient (mmHg), mean (SD) 11.8 (7.5) 14.8 (15.1)
Regurgitation, grade 0–3, mean (SD) 0.42 (0.49) 0.53 (0.57)
LV ejection fraction (%), mean (SD) 64.2 (4.3) 62.7 (8.4)
DAH: decellularized aortic homograft; SD: standard deviation.
Figure 1: Patient inclusion within the prospective multicentre ARISE trial by centre.














































































Initial follow-up results within the prospective
ARISE study cohort
After a mean follow-up of 1.54 ± 0.81 years, the primary efficacy
end points of mean peak gradient (11.8 ± 7.5mmHg) and regurgi-
tation (mean 0.42 ± 0.49, grade 0–3) were excellent.
Freedom from explantation, endocarditis, bleeding and stroke
at 2.5 years was 98.4 ± 1.1%, 99.4 ± 0.6%, 99.1 ± 0.9% and
99.2 ± 0.8%, respectively. These results were almost identical to
those from the age-matched Ross cohort of 212 patients (mean
age 34 years) despite a higher number (>2) of previous proce-
dures in DAH patients [17]. Figure 2 gives an example by demon-
strating the preoperative situation and postoperative course of
the first patient included in the ARISE study.
Figure 3 shows freedom from death and freedom from
homograft explantation for the 144 ARISE Trial patients.
Figure 4 shows freedom from stenosis and regurgitation, and
Fig. 5 displays freedom from any reintervention and freedom
from endocarditis.
Comparison with published Ross-autograft
procedure cohorts
Table 2 lists freedom from diverse adverse outcomes within the
ARISE study (n = 144) and the ARISE Registry (n = 223) compared
with the Ross cohort published by David et al. [17] (n = 212) and
a large recent Ross review provided by Takkenberg et al. [16]
summarizing published results from 6892 adult patients. The
DAH results were comparable to the Ross results for freedom
from death, endocarditis, major bleeding and thrombotic events
at 5 years follow-up. Freedom from reoperation and freedom
from valve degeneration was lower in DAH patients, who were
younger (28.7 ± 19.8 vs 41.9 ± 11.4 years) with paediatric patients
comprising 38% of the ARISE Registry cohort.
Expected adverse events for contemporary aortic
valve replacement options for young adults
Perioperative and annual adverse events such as death, reopera-
tion or reintervention, valve degeneration, thrombotic and
bleeding events and endocarditis were calculated for convention-
al aortic bioprostheses, mechanical valves, the Ross procedure
and DAH to provide an overview of expected adverse events per
patient. Data were taken from recent large-scale meta-analyses
from Takkenberg et al. [4, 15, 16].
Figure 6 shows DAH in young adults with comparable per-
formance to the conventional alternatives of mechanical valves,
the Ross procedure and standard bioprostheses.
DISCUSSION
Surgeons counselling young patients referred for AVR are regu-
larly confronted with the limitations of today’s surgical arsenal.
As a consequence, decision-making tends to be influenced by
the patient’s lifestyle and feared restrictions to quality of life. This
has led to an increasing trend towards bioprosthetic aortic valves
for younger patients despite higher reoperation rates, in part
Figure 2: Twenty four-year-old male patient, 1/2009 aortic valve replacement with 25mm Carpentier Edwards Perimount valve (will of patient) and supracommissural
replacement of the ascending aorta using a 24-mm Hemashield vascular prosthesis. (A, B) Severe calcified aortic stenosis and impaired left ventricular function with
pleural effusion. (C, D) Extended aortic valve replacement including the Hemashield prosthesis using a long decellularized homograft provided by the European
Homograft Bank and explanted bioprosthesis. (E, F) CMR at discharge. (G, H) Postoperatively LV function recovery due to a large effective orifice area and normal







































































































driven by the low incidence of mortality (in some cases 2.5%)
reported for redo AVR [3, 18]. However, this can be misleading,
as the population-based 30-day mortality rate for redo AVR has
been demonstrated to be as high as 4.8% in patients aged 18–55
[2, 3].
In general, the Ross operation is a good option for a young
adult patient as reoperation rates in the first 2 decades are low
[19]. However, it is highly likely that repeated 2-valve surgery will
be necessary within the lifetime of these patients and future re-
search will have to assess whether this negatively impacts long-
term survival after 3 or more decades [16].
Intra-annular procedures are preferred by many surgeons and
centres to reduce operative complexity, due to concerns regard-
ing an increased risk for perioperative mortality in aortic root
procedures. However, recent data from large-scale meta-analyses
focusing only on AVR in young adults suggest that early mortality
for the Ross operation is even lower than for bioprosthetic or
mechanical AVR [4, 15, 16]. In addition, the 10-year mortality
rates for bioprosthetic and mechanical AVR were poorer than
those for the Ross operation [3, 17].
Nevertheless, a large group of patients, including patients with
congenital heart defects or multiple previous surgical procedures,
are not good candidates for the Ross procedure, limiting its
application.
The current study adds important information on alternatives
for AVR, as the ARISE study is the first prospectively conducted
multicentre trial on DAHs as an additional biological option for
AVR in young patients. The results show excellent early haemo-
dynamic results and no specific problems in terms of periopera-
tive handling issues. The early mortality rates were almost
identical to those reported for Ross patients [16, 17, 20, 21],
which is excellent given the 2 times higher rates of previous aor-
tic valve procedures in the DAH cohort. Coronary reimplantation
in DAH was uncomplicated with no need for intraoperative by-
pass grafting. In the Ross procedure, the rate for intraoperative
coronary artery bypass grafting has been reported as 5% in
young adults and 6.5% in children [16]. Given the widespread ex-
pertise in aortic root remodelling techniques such as the David
procedure, we do not consider reimplantation of regular coron-
ary arteries to be a factor likely to influence the outcome of the
DAH cohort. Long-term patency has been shown for reimplanted
coronary arteries in aortic root remodelling techniques and ex-
cellent results have been achieved for redo aortic root surgery
[22]. Data from the ARISE Registry covering all implanted DAH to
date with follow-up data of up to 11 years showed current DAH
results to be well comparable with the contemporary results
achieved with the Ross procedure (Fig. 6).
Decellularized aortic allografts have shown less HLA-response
in humans and less calcification in animal models and in humans
[23–25]. We have shown the absence of calcium in a DAH reop-
eration 4.5 years after implantation in an infant [9] and extensive
in vivo recellularization with non-immunogenic recipient cells in
Figure 4: Freedom from aortic valve stenosis and regurgitation for the ARISE study patients.
Figure 3: Freedom from death and freedom from allograft explantation for the ARISE study patients.














































































decellularized pulmonary and aortic allografts [26]. Decellularized
pulmonary homografts showed significantly higher freedom
from reoperation at 10 years compared with cryopreserved pul-
monary homografts and almost no early cellular immune re-
sponse [10, 27]. The promising initial clinical results for DAH [9]
led to the initiation of prospective multicentre trial, whose early
results are reported here.
Given their restricted availability, which patients stand to bene-
fit most from the implantation of a DAH? Clearly, patients who
underwent multiple previous aortic root procedures during
childhood or young patients after destructive endocarditis and
patients with contraindications for the Ross operation or anticoa-
gulation come into question here. Young adult female patients
who would like to have children and in whom previous biopros-
theses have failed are also good candidates, as permanent antico-
agulation is not required. In addition, young patients with
reduced LV function also are potential recipients for DAH, as
homografts provide excellent effective orifice areas compared
with intra-annular devices. Endocarditis, to our understanding, is
not an indication for DAH, as the open matrix of a decellularized
Table 2: Freedom from diverse adverse outcomes for DAHs within the ARISE study and the ARISE Registry compared with the Ross
cohort published by David et al. [17] and a large recent Ross review published by Takkenberg et al. [16]
Freedom from (%) Cohort At 2.5 years (%), mean ± SD At 5 years (%), mean ± SD
Death ARISE(n = 144) 98.0 ± 1.2 NA
All DAH(n = 223) 98.2 ± 0.9 98.2 ± 0.9
Ross(n = 212) [17] NA 98.6
Ross(n=6892) [16] NA 97.0
Endocarditis ARISE 99.4 ± 0.6 NA
All DAH 99.1 ± 0.9 97.3 ± 2.2
Ross [17] NA 100
Ross [16] NA 98.4
Aortic valve reoperation (explantation or repair) ARISE 98.4 ± 1.1 NA
All DAH 97.5 ± 1.3 90.8 ± 4.0
Ross [17] NA NA
Ross [16] NA 96.7
Aortic stenosis (>50 mmHg peak) ARISE 97.5 ± 1.4 NA
All DAH 94.0 ± 2.4 92.4 ± 2.8
Ross [17] NA NA
Ross [16] NA NA
Aortic regurgitation (>_moderate) ARISE 95.8 ± 1.9 NA
All DAH 96.0 ± 1.8 91.1 ± 3.8
Ross [17] NA 95.2
Ross [16] NA NA
Aortic valve degeneration (stenosis and regurgitation) ARISE 93.3 ± 2.3 NA
All DAH 90.2 ± 2.8 85.3 ± 4.3
Ross [17] NA NA
Ross [16] NA 95.9
Major bleeding ARISE 99.1 ± 0.9 NA
All DAH 99.5 ± 0.5 99.5 ± 0.5
Ross [17] NA 100
Ross [16] NA 99.5
Thrombotic event/stroke ARISE 99.2 ± 0.8 NA
All DAH 99.5 ± 0.5 99.5 ± 0.5
Ross [17] NA 100
Ross [16] NA 99
DAH: decellularized aortic homograft; NA: not applicable; SD: standard deviation.







































































































allograft may be more prone for bacterial invasion. Moreover,
recellularization with patient’s non-immune competent cells is
the aim, which may be reduced in the setting of an active bacter-
ial infection. Therefore, we consider active endocarditis as a
contraindication for DAH.
The limited availability of adequately sized allografts is a draw-
back for DAH and availability is likely to be increasingly challeng-
ing if the long-term results correspond with the excellent short-
to-medium results achieved to date and may also have an impact
on the availability of conventional allografts for the treatment of
aortic root endocarditis. Further research into xenogeneic alter-
natives using genetically modified animals is therefore needed.
The current price for a decellularized homograft, either aortic or
pulmonary, is roughly 20.000 e, which is divided in 4500–5000 e
for the allograft procurement by the providing tissue bank, which
also is allocating the homograft to a certain hospital. Fees for
decellularization are currently 15 000 e and expected to come
down as with any new technology over time development costs
have been reimbursed. The price of the Melody transcatheter
pulmonary valve at market introduction was in the same range
and decreased by 30% over the years. One study on tissue-
engineered pulmonary valves showed the potential to be cost-
effective [28].
Limitations
The short overall follow-up available for DAH patients so far is
the biggest limitation for the study, and definitive conclusions
will require a longer follow-up period. Moreover, there are sev-
eral limitations to the present study, including the one-armed
study design and the restrictions inherent in the comparison of
prospectively collected data from a controlled trial with retro-
spectively conducted single-centre analyses and meta-analyses
based on such reports.
In addition, the transferability of direct conclusions from this
study to other proprietary decellularization protocols is limited
due to the variable influence of the individual protocols on cell
removal, matrix preservation and subsequently allograft im-
munogenicity. Cost aspects have not been addressed within this
analysis, as long-term efficacy for DAH is not available yet.
CONCLUSION
The initial results of the prospective multicentre ARISE trial dem-
onstrate DAH to be safe for AVR with excellent haemodynamics
in the short follow-up period available thus far. Early DAH results
compare well with the early outcomes of contemporary Ross op-
eration cohorts despite 2 times more previous cardiac proce-
dures in DAH patients. The planned follow-up period of at least
10-(20) years will help to determine the suitability of DAH as a
robust, long-term biological AVR option for young patients.
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Figure 6: ARISE Registry data of all 223 decellularized aortic homograft (DAH) implanted to date compared with recently published meta-analysis data from several
AVR options in young adult patients. Perioperative and annual adverse events such as death, reoperation or reintervention, valve degeneration, thrombotic and bleed-
ing events and endocarditis were summarized to provide an estimate of adverse events in the long term. Additionally, actually observed adverse DAH events are
shown in Kaplan–Meier function equivalent ±95% CI. Data taken from Refs [4, 15, 16]. AVR: aortic valve replacement; CI: confidence interval.
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